Mode
Text Size
Log in / Sign up
Phase 2 N=256 Randomized Quadruple-blind Prevention

Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury

Intraventricular Hemorrhage · Periventricular Leukomalacia · Brain Injury · Renal Injury

Enrolled (actual)
256
Serious AEs
9.8%
Results posted
Dec 2020
Primary outcome: Primary: Percent of Survivors With no Severe IVH (Grades 3 or 4) or PVL — 22.2; 14.9; 17.1; 10.9 percent of participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Indomethacin (Drug); delay in umbilical cord clamp at birth (Procedure); placebo infusion (Drug); immediate cord clamp at birth (Procedure)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
Hong Huang
Primary completion
Oct 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent of Survivors With no Severe IVH (Grades 3 or 4) or PVL
22.2; 14.9; 17.1; 10.9
SECONDARY
Number of Participants With Acute Kidney Injury
20; 48; 23; 48; 8; 27

Summary

Intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL) are brain lesions that commonly occur in preterm infants and are well-recognized major contributors to long-term brain injury and related disabilities later in life. Despite its prevalence, long term consequences, and enormous medical and social costs, mechanisms of IVH and optimal strategies to prevent or treat its occurrence are poorly defined, especially for extremely premature infants. Only one medical therapy, prophylactic indomethacin during the first 3 days of life, has been shown to prevent or decrease the severity of IVH in preterm infants, but its use is limited by toxic side effects and debatable effects on long-term outcomes. Several small studies and case reports suggest that delayed umbilical cord-clamping (DCC) may also decrease the incidence of IVH in premature infants, but thus far these trials have indomethacin treatment mixed within their cord clamping protocols. The investigators are conducting a randomized, blinded investigation of 4 treatment groups: 1) Control (no intervention); 2) DCC alone; 3) Prophylactic indomethacin alone; 4) Combination of DCC/indomethacin, with respect to survival, IVH or PVL incidence and severity, neurodevelopmental outcomes, and relevant mechanistic effects. With the steady rise in extreme prematurity births and clear links of IVH to long-term disabilities there is a need to improve care for these patients. This multi- disciplinary project addresses an important medical problem for an understudied patient population, where the current practice has clear limitations.

Eligibility Criteria

Inclusion Criteria

  • pregnant women admitted >24weeks and 30weeks at birth
  • maternal risks identified by obstetrician
  • fetal risks identified by obstetrician
  • any congenital abnormality of newborn infant
  • placental abruption/placental previa
  • delivery less than 2hrs from consenting to study participation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02221219). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search